|By PR Newswire||
|March 18, 2014 05:00 PM EDT||
DUBLIN, March 18, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/wlrph9/china_patent) has announced the addition of the "Concise Analysis of the International Chinese Patent Medicine Industry" report to their offering.
Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance with specified prescription and standard. Chinese patent medicine industry covers the upstream Chinese herbal medicine production and preliminary processing, the middle pharmaceutical sectors as well as downstream commercial institutions of drug circulation and sales.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Currently, the State is enhancing its support for the Chinese patent medicine industry, successively introducing the Continuing Improving TCM Healthcare Policy, Notice on Conducting Construction of Key Projects of TCM Trade in Services and other favorable policies in 2013. In 2010-2013, China's Chinese patent medicine industry developed rapidly, with revenue soaring from RMB215.4 billion to RMB448.2 billion at a CAGR of 27.7%.
According to hospital terminal data, Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases and respiratory system diseases are the top three categories of Chinese patent medicine in China, respectively accounting for 37.2%, 15.4% and 11.1% market share in 2012-2013. As far as the distribution of Chinese patent medicine formulations is concerned, there is a clear trend of convergence in injection, and injection formulation products in the top three categories of Chinese patent medicine all made up above 50%.
Cardiovascular and cerebrovascular disease market is the biggest market for Chinese patent medicine, but also the most-variety field with item sales of over RMB500 million.
Key Topics Covered:
1. Overview of Chinese Patent Medicine
2. Operating Environment for Chinese Patent Medicine Industry
3. Chinese Patent Medicine Market
4. Chinese Patent Medicine Market Segments in China
5. Key Enterprises
6. Summary and Forecast
- Beijing Tongrentang
- China Resources Sanjiu Medical & Pharmaceutical
- Guizhou Yibai Pharmaceutical
- Kangmei Pharmaceutical
- Shandong Dong-E E-Jiao
- Shanghai Kaibao Pharmaceutical
- Tianjin Tasly Pharmaceutical
- Tibet Rhodiola Pharmaceutical Holding
- Yunnan Baiyao Group
- Zhangzhou Pientzehuang Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/wlrph9/china_patent
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Jun. 3, 2015 05:30 AM EDT Reads: 2,033
Jun. 3, 2015 05:30 AM EDT Reads: 4,456
Jun. 3, 2015 05:00 AM EDT Reads: 4,484
Jun. 3, 2015 04:00 AM EDT Reads: 822
Jun. 3, 2015 04:00 AM EDT Reads: 5,048
Jun. 3, 2015 04:00 AM EDT Reads: 2,738
Jun. 3, 2015 04:00 AM EDT Reads: 1,270
Jun. 3, 2015 03:15 AM EDT Reads: 2,432
Jun. 3, 2015 03:15 AM EDT Reads: 3,591
Jun. 3, 2015 03:00 AM EDT Reads: 861
Jun. 3, 2015 02:30 AM EDT Reads: 2,974
Jun. 3, 2015 02:15 AM EDT Reads: 3,135
Jun. 3, 2015 02:00 AM EDT Reads: 4,637
Jun. 3, 2015 01:15 AM EDT Reads: 2,426
"In our world there's a lot of cloud. Our focus is to help companies, who are bogged down by the enormousness of the cloud and infrastructure, to really go out there and monetize the cloud," explained Ian Khan, Global Strategic Positioning & Brand Manager at Solgenia, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Jun. 3, 2015 01:00 AM EDT Reads: 3,461